Tag archive for ‘DCVax-L survival tail in newly diagnosed glioblastoma’
Northwest Biotherapeutics: Management’s Decision to Determine Survival Tail for DCVax-L in Phase 3 Trial in Newly Diagnosed Glioblastoma Was Absolutely the Right Move (NWBO, Buy, $0.25)
Key Points: NWBO is approaching unblinding of the critical phase 3 trial of DCVax-L in newly diagnosed glioblastoma (GBM). Management let the trial run longer in order to determine if there is a survival tail. This should prove critical to potential regulatory approval and commercialization. A meaningful survival tail has been key to the huge […]